Literature DB >> 19443578

Activator protein-2 impairs the invasion of a human extravillous trophoblast cell line.

Tomomi Kotani1, Akira Iwase, Kazuhiko Ino, Seiji Sumigama, Eiko Yamamoto, Hiromi Hayakawa, Tetsuo Nagasaka, Atsuo Itakura, Seiji Nomura, Fumitaka Kikkawa.   

Abstract

The reduced migration/invasion of extravillous trophoblasts (EVTs) is a key feature of the genesis of preeclampsia. We and others previously reported that transcriptional factors activator protein-2 (AP-2) alpha and AP-2gamma act as suppressors of tumor invasion. The present study examined the expressions of AP-2alpha and AP-2gamma in preeclamptic placenta vs. control placenta and investigated their effect on the function of EVTs. The expressions of AP-2alpha and AP-2gamma were elevated in the preeclamptic placentas in comparison with the gestational age-matched control placentas. Their expressions also increased in EVTs of the preeclamptic placentas. Thereafter, we transfected AP-2alpha or AP-2gamma into human EVT cell line, HTR-8/SVneo. The overexpression of AP-2alpha or AP-2gamma decreased the migratory and invasive abilities in HTR-8/SVneo cells. This was followed by the reduction of protease activated receptor-1 and matrix metalloproteinases and a significant induction of plasminogen activator inhibitor-1 and the tissue inhibitor of metalloproteinase-1. AP-2alpha and AP-2gamma were weakly expressed in the cultured EVTs and HTR-8/SVneo cells, whereas they were induced by TNF-alpha, which increases in preeclamptic placenta and impairs trophoblast invasion. In the presence of TNF-alpha, the invasion of the HTR-8/SVneo cells was partially restored by a blocking of AP-2 induction using small interfering RNA of AP-2. The present data suggest that AP-2 may suppress trophoblast migration and invasion, thus leading to a shallow placentation in preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443578     DOI: 10.1210/en.2008-1645

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  AP-2α-dependent regulation of Bcl-2/Bax expression affects apoptosis in the trophoblast.

Authors:  Ling Zhang; Liting Jia; Shihong Cui; Ying Shi; Aimin Chang; Peng Wang; Zhan Zhang
Journal:  J Mol Histol       Date:  2012-08-11       Impact factor: 2.611

2.  Methylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance.

Authors:  J N Jeyapalan; D A Mohamed Noor; S-H Lee; C L Tan; V A Appleby; J P Kilday; R D Palmer; E C Schwalbe; S C Clifford; D A Walker; M J Murray; N Coleman; J C Nicholson; P J Scotting
Journal:  Br J Cancer       Date:  2011-06-28       Impact factor: 7.640

3.  AP-2α suppresses invasion in BeWo cells by repression of matrix metalloproteinase-2 and -9 and up-regulation of E-cadherin.

Authors:  Zhan Zhang; Ling Zhang; Liting Jia; Shihong Cui; Ying Shi; Aimin Chang; Xianxu Zeng; Peng Wang
Journal:  Mol Cell Biochem       Date:  2013-05-10       Impact factor: 3.396

4.  Abnormal expression of transcription factor activator protein-2α in pathologic placentas.

Authors:  Rachel M Sheridan; Jerzy Stanek; Jane Khoury; Stuart Handwerger
Journal:  Hum Pathol       Date:  2012-05-09       Impact factor: 3.466

5.  MicroRNA-576-5p enhances the invasion ability of trophoblast cells in preeclampsia by targeting TFAP2A.

Authors:  Xiaoning Wang; Shiyuan Peng; Kun Cui; Fangjuan Hou; Jie Ding; Ali Li; Mingxia Wang; Li Geng
Journal:  Mol Genet Genomic Med       Date:  2019-11-08       Impact factor: 2.183

6.  The Novel Peptide AEDPPE Alleviates Trophoblast Cell Dysfunction Associated With Preeclampsia by Regulating the NF-κB Signaling Pathway.

Authors:  Yixiao Wang; Yan Cao; Xiaohong Ji; Ting Li; Lu Xue; Chanjuan Li; Ruizhe Jia; Hongjuan Ding
Journal:  Front Cardiovasc Med       Date:  2021-12-17

7.  Landscape of transcriptional deregulations in the preeclamptic placenta.

Authors:  Daniel Vaiman; Rosamaria Calicchio; Francisco Miralles
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.